Agenda will run 8.20am - 6.00pm CET
8:00 am Virtual Coffee Networking Morning
8:20 am Chair’s Opening Remarks
Precision Medicine Application Across an Evolving European Landscape: Exciting Advancements & Current Socio-Political Environment
8:30 am The Translational Perspective: Early Biomarker Decisions Today to Influence Precision Medicine Successes of Tomorrow
Synopsis
- Starting with the end in mind: Early biomarker decisions for down the line precision medicine success and optimise outcomes for patients
- Working with your stakeholders to devise a robust biomarker programme
- Bridging the preclinical and clinical gap, and translating clinically validated predictive biomarkers with improved treatment outcomes
9:00 am Moving Diagnostic Providers to the Forefront of Precision Medicine
Synopsis
• Role of the Diagnostic Laboratory in CDx commercialization – Key Considerations and Day 1 Readiness
• CDx Case Studies including PIK3CA – discussing the full spectrum of CDx development from bench to bedside
• Lab Challenges: Perspectives on lessons learned and future paradigms for CDx/Dx development
9:30 am Pharma & Central Lab – An Innovative Way of Working for Deployment of a Successful Companion Diagnostic Development Program
Synopsis
• Alignment on objectives to deliver CDx data from a global study across 4 locations
• Pioneering an innovative Operational Model to enhance success
• Challenges and mitigation
10:00 am Panel Discussion: Current Socio-Political & the Changing Healthcare Landscape Influences on Precision Medicine Delivery in the EU
Synopsis
- Implications of Covid-19 on the delivery of precision medicine
- Following Brexit: How are impacts being felt across the industry and potential disruptions to targeted therapy development
- Precision medicine in the EU: A leading precision medicine market but where can we improve? Highlighting challenges connecting a diverse landscape to deliver better treatment outcomes
- With IVDR regulations coming into effect in just over a year in the EU – Where are we now? What bottlenecks are foreseen for precision medicine implementation come May 2022?
10:45 am Speed Networking & Coffee Networking Break
12:45 pm Networking Lunch
Synopsis
Whilst enjoying a bite to eat, you can take part in:
- 121 Pre-Scheduled Meetings With Our Event Partners: Take part in 1:1 networking with market leaders pioneering exciting advances in the biomarker-driven drug development space
- Group Networking: Join your fellow attendees for groups discussions reflecting on the morning’s topics. Collaborate and connect to consider applying new ideas and innovations to propel your pipelines forward
3:15 pm Afternoon Speed Networking Break
3:45 pm Panel Discussion: Women & Diversity in Precision Medicine
Synopsis
This panel discussion is designed to bring value to all leaders in healthcare looking to unlock the potential of their team, career and business. Through tapping into multiple diverse perspectives and experiences we can accelerate innovation and drive progress in the provision of personalised care.
Data & Advanced Technology in Rare Disease: Generating Insights for Faster & More Focussed Patient Stratification
Moderator: Guillaume Desachy, Principal Biostatistician, AstraZeneca
4:45 pm Harnessing Transcriptional Profiling for Immune-Based Cancer Patient Stratification
Synopsis
- Deconvolution of bulk gene expression tumour data allows for a comprehensive quantification of a complete set of immune cell fractions within the tumor context
- The quantification of immune cell fractions can contribute to identify those immune cell types which may have a role in patient survival, and therefore contribute to a more precise stratification of patients based on their predicted prognosis
- The use of functional signatures of drug response can also contribute to identify potential therapeutic strategies specific for each one of the identified immune-based groups
5:15 pm NY-ESO-1 TCR T-cell Therapy in Synovial Sarcoma
Synopsis
• Letetresgene autoleucel (lete-cel; GSK3377794) is a T-cell receptor (TCR) T-cell therapy specific to the NY-ESO-1 peptide-displaying antigen, a highly immunogenic cancer/testis antigen expressed in synovial sarcoma, that promotes an anticancer immune response.
• A Phase I study in patients with previously-treated advanced synovial sarcoma whose tumors express NY-ESO-1 protein indicated that lete-cel infusion was associated with response rates.
• Early development of NY-ESO-1 immunohistochemistry detection suggests a companion diagnostic path forward clinical development.
5:45 pm Chair’s Closing Remarks
6:00 pm End of Day 1
Synopsis
Just because we can’t meet in person, doesn’t mean you can’t have those face to face interactions with your precision oncology peers. Take part in group networking or use the private chat functions to meet fresh and familiar faces and reflect on Day One of the meeting.
We look forward to welcoming you back for Day Two!